Sozinibercept is under clinical development by Opthea and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sozinibercept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sozinibercept overview
OPT-302 (VGX-300) is under development for the treatment of wet age-related macular degeneration and diabetic macular edema. The drug candidate is administered through the intravitreal route. It is a soluble fusion protein comprising of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of human immunoglobulin G1 (IgG1). The drug candidate acts by targeting vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D). It was also under development for the treatment of solid tumors.
Opthea overview
Opthea formerly Circadian Technologies, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vascular endothelial growth factors. Its pipeline products include VEGF-C, VEGF-D and VEGFR-3. Opthea’s lead compound, OPT-302 is used in combination with existing VEGF-A inhibitors in patients with age-related macular degeneration and diabetic macular edema. The company’s VEGF-D diagnostics is a prognostic indicator of number of tumor types, and VEGF-C diagnostics, an indicator of survival rate. It partners with healthcare and diagnostic centers. Circadian is headquartered in Melbourne, Victoria, Australia.
For a complete picture of Sozinibercept’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
